Fragment space searches in pharmaceutical research

webinar

Thu, 18 Aug 2016, 15:00 CEST (Berlin)

Dr. Uta Lessel, Principal Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG

Fragment space searches in pharmaceutical research

Chemical fragment spaces consist of molecular fragments and corresponding connection rules. The introduction of this talk deals with the question why searches in chemical fragment spaces are valuable for pharmaceutical research. Then the generation of FTrees Fragment Spaces with CoLibri and the integration of fragment space searches in the drug discovery process at Boehringer Ingelheim are presented. Finally, an application example is shown.

Current news

category
Challenge
Winter 2025 Scientific Challenge Deadline Approaching
November 10, 2025 10:38 CET
We invite researchers in academia (students, postdocs, professors), non-profit organizations, and individuals to participate in our quarterly Scientific Challenge. Take advantage of our wide array of software to help meet your drug discovery goals. How to Participate Just send us a proposal for the project you would like to advance...
Read on
category
Events
Recordings of the BioSolveIT Day 2025 Available
October 15, 2025 13:39 CEST
Missed BioSolveIT Day 2025? The recordings from BioSolveIT Day 2025 are now live! Packed with practical insights for medicinal and computational chemists, the sessions showcase how SeeSAR, infiniSee, Chemical Space Docking®, and CoLibri accelerate real-world discovery, from pocket-aware design and HYDE-guided decisions to trillion-scale, synthesizable chemical space exploration and in-house...
Read on
Enamine’s REAL Space September 2025 Update - Now 83 Billion!
September 23, 2025 10:31 CEST
The September 2025 update of Enamine’s REAL Space brings a new expansion, now featuring over 83 billion accessible, drug-like products, up from 76 billion in the previous release. Built from 172 curated reactions and 192,487 reagents and building blocks based on in-house knowledge, this version further enhances one of the...
Read on